179 related articles for article (PubMed ID: 38132219)
1. Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract.
Fujii S; Ishida M; Komura K; Nishimura K; Tsujino T; Saito T; Taniguchi Y; Murakawa T; Azuma H; Hirose Y
Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132219
[TBL] [Abstract][Full Text] [Related]
2. Periocular Sebaceous Carcinoma: A Case Audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022 to Assess the Diagnostic Utility of PRAME Expression.
Salleh AA; Krishna Y; Coupland SE
Ocul Oncol Pathol; 2024 Apr; 10(1):1-8. PubMed ID: 38645737
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis.
Ricci C; Franceschini T; Giunchi F; Grillini M; Ambrosi F; Massari F; Mollica V; Colecchia M; Fiorentino M
Am J Clin Pathol; 2022 May; 157(5):644-648. PubMed ID: 34864837
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
5. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17.
Zhou Y; Rothrock A; Murugan P; Li F; Bu L
Exp Mol Pathol; 2022 Jun; 126():104761. PubMed ID: 35390309
[TBL] [Abstract][Full Text] [Related]
7.
Pankov D; Sjöström L; Kalidindi T; Lee SG; Sjöström K; Gardner R; McDevitt MR; O'Reilly R; Thorek DLJ; Larson SM; Veach D; Ulmert D
Oncotarget; 2017 Sep; 8(39):65917-65931. PubMed ID: 29029482
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Jungbluth AA; Katabi N; Xu B; Downes MR
Virchows Arch; 2020 Apr; 476(4):535-542. PubMed ID: 31485721
[TBL] [Abstract][Full Text] [Related]
10. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee PH; Lang H; Cruz CRY; Hanley PJ; Barrett AJ; Keller MD; Bollard CM
Cytotherapy; 2021 Aug; 23(8):694-703. PubMed ID: 33832817
[TBL] [Abstract][Full Text] [Related]
12. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
[TBL] [Abstract][Full Text] [Related]
13. Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma.
Oyama K; Kanki K; Shimizu H; Kono Y; Azumi J; Toriguchi K; Hatano E; Shiota G
Gastrointest Tumors; 2017 Mar; 3(3-4):128-135. PubMed ID: 28611979
[TBL] [Abstract][Full Text] [Related]
14. Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients.
Kulkarni NV; Shetty RA; Kumari N S; Shetty VV; Krishna R; Arumugam M; Kalal AA; Shetty P
J Genet Eng Biotechnol; 2022 Jul; 20(1):97. PubMed ID: 35788450
[TBL] [Abstract][Full Text] [Related]
15. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.
Lee YK; Heo HH; Kim N; Park UH; Youn H; Moon EY; Kim EJ; Um SJ
BMB Rep; 2024 Jun; 57(6):299-304. PubMed ID: 38835116
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
17. Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al-Khadairi G; Decock J
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31311081
[TBL] [Abstract][Full Text] [Related]
18. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD; Gradecki SE; Mills AM
Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
[TBL] [Abstract][Full Text] [Related]
19. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
Hermes N; Kewitz S; Staege MS
Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
[TBL] [Abstract][Full Text] [Related]
20. PRAME immunohistochemistry is useful in the diagnosis of oral malignant melanoma.
Hovander D; Allen J; Oda D; Moshiri AS
Oral Oncol; 2022 Jan; 124():105500. PubMed ID: 34452831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
